Autologous Chondrocyte Implantation in the Patellofemoral Joint

NCT00212849 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 35

Last updated 2005-09-21

No results posted yet for this study

Summary

The purpose of this study is to measure the outcomes of patients who have articular cartilage lesions in the patellofemoral joint and are treated with the Autologous Chondrocyte Implantation.

Conditions

  • Chondrosis
  • Patellar Articular Cartilage Lesions
  • Trochlear Articular Cartilage Lesions

Sponsors & Collaborators

  • Genzyme, a Sanofi Company

    collaborator INDUSTRY
  • Orthopaedic Research Foundation

    lead OTHER

Principal Investigators

  • Jack Farr, MD · Orthopaedic Research Foundation, Inc.

Eligibility

Min Age
18 Years
Max Age
50 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
1995-01-31
Completion
2005-08-31

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00212849 on ClinicalTrials.gov